Hims & Hers Health (HIMS) Competitors $47.91 -2.36 (-4.69%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$48.04 +0.14 (+0.28%) As of 07/11/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HIMS vs. NTRA, GH, OPCH, RDNT, BTSG, SHC, SGRY, PRVA, CON, and WGSShould you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), and GeneDx (WGS). These companies are all part of the "healthcare" industry. Hims & Hers Health vs. Its Competitors Natera Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Privia Health Group Concentra Group Holdings Parent GeneDx Hims & Hers Health (NYSE:HIMS) and Natera (NASDAQ:NTRA) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Do insiders & institutionals believe in HIMS or NTRA? 63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 13.7% of Hims & Hers Health shares are owned by insiders. Comparatively, 7.6% of Natera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor HIMS or NTRA? In the previous week, Hims & Hers Health had 75 more articles in the media than Natera. MarketBeat recorded 84 mentions for Hims & Hers Health and 9 mentions for Natera. Natera's average media sentiment score of 1.57 beat Hims & Hers Health's score of 0.25 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 17 Very Positive mention(s) 2 Positive mention(s) 59 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Natera 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is HIMS or NTRA more profitable? Hims & Hers Health has a net margin of 9.24% compared to Natera's net margin of -10.36%. Hims & Hers Health's return on equity of 22.75% beat Natera's return on equity.Company Net Margins Return on Equity Return on Assets Hims & Hers Health9.24% 22.75% 15.51% Natera -10.36%-18.29%-11.68% Do analysts recommend HIMS or NTRA? Hims & Hers Health currently has a consensus target price of $39.58, indicating a potential downside of 17.38%. Natera has a consensus target price of $184.63, indicating a potential upside of 15.08%. Given Natera's stronger consensus rating and higher possible upside, analysts plainly believe Natera is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hims & Hers Health 3 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92Natera 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, HIMS or NTRA? Hims & Hers Health has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Which has better valuation & earnings, HIMS or NTRA? Hims & Hers Health has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHims & Hers Health$1.48B7.26$126.04M$0.6969.43Natera$1.70B12.91-$190.43M-$1.47-109.14 SummaryHims & Hers Health beats Natera on 9 of the 16 factors compared between the two stocks. Get Hims & Hers Health News Delivered to You Automatically Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HIMS vs. The Competition Export to ExcelMetricHims & Hers HealthMEDICAL INFO SYS IndustryMedical SectorNYSE ExchangeMarket Cap$11.25B$2.00B$5.62B$20.73BDividend YieldN/AN/A5.24%3.71%P/E Ratio69.4434.5628.1827.84Price / Sales7.2611.10428.7042.31Price / Cash142.7556.3037.4622.63Price / Book22.188.368.044.57Net Income$126.04M-$62.39M$3.19B$989.30M7 Day Performance-0.01%5.08%3.62%0.20%1 Month Performance-15.78%8.13%4.06%3.95%1 Year Performance120.68%5.64%30.00%10.27% Hims & Hers Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HIMSHims & Hers Health2.0833 of 5 stars$47.91-4.7%$39.58-17.4%+127.7%$11.25B$1.48B69.441,637Trending NewsAnalyst DowngradeInsider TradeNTRANatera1.645 of 5 stars$159.36-1.5%$184.63+15.9%+44.8%$21.75B$1.70B-108.374,434Positive NewsGHGuardant Health4.1208 of 5 stars$49.32-2.3%$53.76+9.0%+67.7%$6.13B$739.02M-14.592,021OPCHOption Care Health4.5522 of 5 stars$30.90-0.8%$35.50+14.9%+3.2%$5.06B$5.00B24.928,088News CoveragePositive NewsAnalyst ForecastRDNTRadNet4.1912 of 5 stars$55.62-1.0%$69.60+25.1%-7.3%$4.17B$1.83B-129.2811,021Positive NewsAnalyst ForecastBTSGBrightSpring Health Services1.6864 of 5 stars$21.99-0.6%$24.90+13.2%+83.0%$3.86B$11.27B78.5235,000SHCSotera Health3.1714 of 5 stars$11.43-2.8%$16.00+40.0%-3.2%$3.24B$1.11B142.833,000SGRYSurgery Partners2.4634 of 5 stars$22.08-0.3%$33.56+52.0%-13.7%$2.83B$3.11B-14.4415,000PRVAPrivia Health Group4.5043 of 5 stars$21.41-3.2%$27.77+29.7%+14.2%$2.61B$1.74B178.351,140News CoverageAnalyst ForecastCONConcentra Group Holdings Parent2.9448 of 5 stars$20.29-1.3%$28.50+40.5%N/A$2.60B$1.90B15.1511,250News CoverageWGSGeneDx3.8521 of 5 stars$85.17-7.0%$90.13+5.8%+141.3%$2.43B$305.45M-60.331,200Trending NewsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies NTRA Competitors GH Competitors OPCH Competitors RDNT Competitors BTSG Competitors SHC Competitors SGRY Competitors PRVA Competitors CON Competitors WGS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HIMS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hims & Hers Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
